Cefmatilen

Drugbox
IUPAC_name = (6"R",7"R")-7-{ [(2"Z")-2-(2-amino-1,3-thiazol-4-yl)- 2-(hydroxyimino)acetyl] amino}-8-oxo-3-{ [("1"H-1,2,3- triazol-4-ylsulfanyl)methyl] sulfanyl}-5-thia-1- azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid

---

width = 280
CAS_number = 140128-74-1
CAS_supplemental = CAS|154776-45-1 (HCl · H₂O)
ATC_prefix =
ATC_suffix =
PubChem = 9690121
DrugBank =
C=15 |H=14 |N=8 |O=5 |S=4
molecular_weight = 514.582 g/mol
smiles = C1C(=C(N2 [C@H] (S1) [C@@H] (C2=O)NC(=O)/C(=NO)/C3=CSC(=N3)N)C(=O)O)SCSC4=NNN=C4
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration = Oral

Cefmatilen (INN, codenamed S-1090) is an orally-active cephalosporin antibiotic. It was developed in Japan and first described in 1992.

"In vitro", cefmatilen is highly active against a variety of Gram-positive and Gram-negative bacteria, including "Streptococcus pyogenes" and "Neisseria gonorrhoeae".cite journal |author=Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K |title=In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin |journal=Antimicrob Agents Chemother |volume=39 |issue=11 |pages=2544–51 |year=1995 |month=November |pmid=8585742 |pmc=162981 |doi= |url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=8585742]

References

Further reading

*cite journal |author=Cazzola M |title=Novel oral cephalosporins |journal=Expert Opin Investig Drugs |volume=9 |issue=2 |pages=237–46 |year=2000 |month=February |pmid=11060674 |doi=10.1517/13543784.9.2.237